Activity and safety of fenspiride in bronchial hyperexudation
De Labarthe, B.; Gosset, X.; Dourmap, C.; Delaval, P.; Le Rest, R.
La Semaine des Hopitaux Organe Fonde Par l'Association d'Enseignement Medical des Hopitaux de Paris 55(33-34): 1549-1552
1979
ISSN/ISBN: 0037-1777 PMID: 42144 Document Number: 143803
This clinical trial of fenspiride (injectable and sustained-release 80 mg tablet) was carried out on patients selected because their bronchopathy was of a hypersecretory type. Interesting results were observed in 20 out of 37 cases, but they were often delayed. This group of patients included a high proportion of patients with major hypersecretion; the efficacy of fenspiride is often evident, (in 8 out of 11 cases) but it is unpredictable individually. It can be concluded from this trial that a long term treatment with fenspiride, well tolerated, can usefully be tried in patients with predominant signs of bronchial hyperexudation.